In the April–June 2015 edition of Corporate Disputes, Dr. Gregory Bell and Professor Iain Cockburn discuss damages in the pharmaceutical and biotech sector . To read more, click on the link below.
ASCO 2024 review: The benefits and barriers of biomarkers in oncology
Biomarkers: what do we mean? – The term “biomarkers” can be broadly clustered into four categories: molecular, histologic, radiographic and physiological. –...